Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Can-Fite licenses arthritis drug to Kwang Dong Pharmaceutical
CF101, Can-Fite’s lead drug, is currently being tested in multi-national Phase IIb study for its therapeutic activity in the treatment of rheumatoid arthritis and in two Phase IIa
CF101, Can-Fite’s lead drug, is currently being tested in multi-national Phase IIb study for its therapeutic activity in the treatment of rheumatoid arthritis and in two Phase IIa
Dr Holman was formerly at Amylin Pharmaceuticals from 2001 to 2007, most recently as executive director of intellectual property. While at Amylin, she led the group responsible for
In conjunction with the cost reduction activities, the company has not renewed its Alameda, California sublease and has vacated its Charlestown, Massachusetts facility. The company is focused on
According to the company, the net proceeds of the private placement will be used to advance the company’s clinical development programs, including lead product JX-594, which is currently
The Pas-Port system is said to create a secure connection, or anastomosis, between a vein graft and the aorta, the main artery in the human body, during coronary
Dr Hughes was formerly vice president and global head of cardiovascular and metabolism disease area at the Novartis Institutes for BioMedical Research in Cambridge, where he directed drug
Located along Maryland’s I-270 technology corridor, the almost 26,000sqft facility will accommodate the company’s future growth needs as the developer and manufacturer of lentiviral vectors (LVs) and proteins
In this Phase II trial, CardioVascular BioTherapeutics’s (CVBT’s) drug candidate containing human Fibroblast Growth Factor-1 (FGF-1), will be injected into patients’ hearts, stimulating a healing process called angiogenesis.
Mr Warden was a founding partner of Yetter, Warden & Coleman. In his 23 years of practice, he has represented both plaintiffs and defendants in cases pertaining to
Under the terms of the agreement, Pharsight stockholders will receive $5.50 in cash for each outstanding share of common stock. The board of directors of Pharsight has unanimously